Long-term immunogenicity after one and two doses of a monovalent MF59-adjuvanted A/H1N1 influenza virus vaccine coadministered with the seasonal 2009-2010 nonadjuvanted influenza virus vaccine in HIV-infected children, adolescents, and young adults in a randomized controlled trial

Clinical and Vaccine Immunology

Volumn 18, Issue 9, 2011, Pages 1503-1509

  Viganò, Alessandra ^a   Giacomet, Vania ^a   Pariani, Elena ^b   Giani, Elisa ^a   Manfredini, Valeria ^a   Bedogni, Giorgio ^c   Erba, Paola ^a   Amendola, Antonella ^b   Zanetti, Alessandro ^b   Zuccotti, Gianvincenzo ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c Liver Research Center   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE; VIRUS RNA;

ADULT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CD4 LYMPHOCYTE COUNT; CHILD; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FLU LIKE SYNDROME; FOLLOW UP; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGENICITY; IMMUNOSTIMULATION; INFECTION PREVENTION; INFLUENZA A (H1N1); INFLUENZA VACCINATION; INJECTION SITE PAIN; MAJOR CLINICAL STUDY; MALAISE; MALE; MIXED INFECTION; OUTCOME ASSESSMENT; PANDEMIC INFLUENZA; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REPEATED DRUG DOSE; SEASONAL INFLUENZA; SEROCONVERSION; SINGLE DRUG DOSE; VACCINATION REACTION; VIRUS LOAD;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; ANTIBODIES, VIRAL; CD4-POSITIVE T-LYMPHOCYTES; CHILD; FEMALE; HIV INFECTIONS; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; PANDEMICS; POLYSORBATES; SEASONS; SQUALENE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 80052446764     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.05200-11     Document Type: Article

References (24)

1. Amendola, A., et al. 2010. Influenza surveillance in a cohort of HIV-infected children and adolescents immunized against seasonal influenza. Vaccine 28:2700-2704.
2. Arguedas, A., et al. 2011. Assessment of the safety, tolerability and kinetics of the immune response to A/H1N1v vaccine formulations with and without adjuvant in healthy pediatric subjects from 3 through 17 years of age. Hum. Vaccin. 7:58-66.
3. Bickel, M., et al. 2011. Immune response after two doses of the novel split virion, adjuvanted pandemic H1N1 influenza A vaccine in HIV-1-infected patients. Clin. Infect. Dis. 52:122-127.
4. Black, S., et al. 2010. Safety of MF59-adjuvanted versus non-adjuvanted influenza vaccines in children and adolescents: An integrated analysis. Vaccine 28:7331-7336.
5. Cagigi, A., A. Nilsson, S. Pensieroso, and F. Chiodi. 2010. Dysfunctional B-cell responses during HIV-1 infection: Implication for influenza vaccination and highly active antiretroviral therapy. Lancet Infect. Dis. 10:499-503.
6. De Carvalho, A. P., L. C. Dutra, and E. Tonelli. 2003. Influenza vaccination in HIV infected children: Immunologic and viral load changes. J. Pediatr. (Rio J.) 79:29-40. (In Portuguese.)
7. Crum-Cianflone, N. F., et al. 2011. Durability of antibody responses after receipt of the monovalent 2009 pandemic influenza A (H1N1) vaccine among HIV-infected and HIV-uninfected adults. Vaccine 29:3183-3191.
8. Dawood, F. S., et al. 2009. Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N. Engl. J. Med. 360:2605-2615.
9. Durando, P., et al. 2008. Safety and immunogenicity of two influenza virus subunit vaccines, with or without MF59 adjuvant, administered to human immunodeficiency virus type 1-seropositive and -seronegative adults. Clin. Vaccine Immunol. 15:253-259. (Pubitemid 352025530)
10. Durando, P., G. Icardi, and F. Ansaldi. 2010. MF59-adjuvanted vaccine: A safe and useful tool to enhance and broaden protection against seasonal influenza viruses in subjects at risk. Expert Opin. Biol. Ther. 10:639-651.
11. Esposito, S., et al. 2011. Pandemic influenza A/H1N1 vaccine administered sequentially or simultaneously with seasonal influenza vaccine to HIV-infected children and adolescents. Vaccine 29:1677-1682.
12. Fitzmaurice, G. M., M. Davidian, G. Verbeke, and G. Molenberghs (ed.) 2008. Longitudinal data analysis. CRC Press, Boca Raton, FL.
13. Garcia-Sicilia, J., et al. 2011. Immunogenicity and safety of AS03-adjuvanted H1N1 pandemic vaccines in children and adolescents. Vaccine 29:4353-4361.
14. Iorio, A. M., et al. 2003. Antibody responses and HIV-1 viral load in HIV-1-seropositive subjects immunised with either the MF59-adjuvanted influenza vaccine or a conventional non-adjuvanted subunit vaccine during highly active antiretroviral therapy. Vaccine 21:3629-3637. (Pubitemid 37338187)
15. Kunisaki, K. M., and E. N. Janoff. 2009. Influenza in immunosuppressed populations: A review of infection frequency, morbidity, mortality, and vaccine responses. Lancet Infect. Dis. 9:493-504.
16. Machado, A. A., et al. 1 March 2011, posting date. Immunogenicity of an inactivated influenza vaccine and postvaccination influenza surveillance in HIV-infected and noninfected children and adolescents. AIDS Res. Hum. Retrovir. [Epub ahead of print.]
17. Orlando, G., et al. 2010. Pandemic influenza vaccine in adult HIV-1-infected patients. AIDS 24:2142-2143.
18. Plennevaux, E., E. Sheldon, M. Blatter, M. K. Reeves-Hoché, and M. Denis. 2010. Immune response after a single vaccination against 2009 influenza A H1N1 in USA: A preliminary report of two randomised controlled phase 2 trials. Lancet 375:41-48.
19. Rabe-Hesketh, S., and A. Skrondal. 2008. Multilevel and longitudinal modeling using StataMultilevel and longitudinal modeling using Stata. Stata Press, College Station, TX.
20. Soonawala, D., G. F. Rimmelzwaan, L. B. Gelinck, L. G. Visser, and F. P. Kroon. 2011. Response to 2009 pandemic influenza A (H1N1) vaccine in HIV-infected patients and the influence of prior seasonal influenza vaccination. PLoS One 6:e16496.
21. Sutcliffe, C. G., and W. J. Moss. 2010. Do children infected with HIV receiving HAART need to be revaccinated? Lancet Infect. Dis. 10:630-642.
22. Tebas, P., et al. 2010. Poor immunogenicity of the H1N1 2009 vaccine in well controlled HIV-infected individuals. AIDS 24:2187-2192.
23. Walter, E. B., et al. 2006. Influenza vaccine immunogenicity in 6- to 23-month-old children: Are identical antigens necessary for priming? Pediatrics 118:e570-e578. (Pubitemid 46091608)
24. World Health Organization (WHO). 2002. WHO manual on animal influenza diagnosis and surveillance. WHO document WHO/CDS/CSR/NCS/ 2002.5. World Health Organization, Geneva, Switzerland. http://www.who.int/vaccine-research/diseases/ influenza/WHO-manual-on-animal -diagnosis-and-surveillance-2002-5.pdf.